Range Biotechnologies (Range Bio) has secured $5.2 million in seed funding, led by ARTIS Ventures with participation from various investors. Their technology enables the precise measurement of multiple proteins in numerous samples simultaneously, offering valuable insights into disease mechanisms and their evolution over time. This funding will support Range Bio’s efforts in developing high-throughput multiplexed protein quantification, which has the potential to revolutionize precision health by enhancing diagnostics, treatment, and prevention strategies for diseases like cancer, cardiovascular disease, COPD, MS, and more.
What You Should Know:
- Range Biotechnologies (Range Bio) announced $5.2M in seed funding, led by TechBio-focused ARTIS Ventures with participation from Pear VC, Page One Ventures, Civilization Ventures, Pillar, Four Cities Capital, Hawktail, and others.
- Proteomics, the study of proteins in the body, has the potential to improve human health in several ways. For example, proteomic studies can help identify which proteins correlate with a certain disease or drug response. Protein biomarkers can be used in personalized health applications, where treatments or diagnoses are tailored to an individual’s specific physiology.
- Range Bio’s technology allows for the accurate quantification of multiple proteins across many samples simultaneously, providing critical insights into the underlying mechanisms of disease and how they change over time. Thus, developing more effective ways to diagnose, treat, and prevent diseases such as cardiovascular disease, cancer, COPD, MS, and more.
- The seed funding will advance Range Bio’s work in high throughput multiplexed protein quantification to enable precision health.
Source: HitConsultant
